Industry
Trusted Guidance in Psychedelics and Other Emerging Therapies.
An increasing body of clinical research is confirming the effectiveness and safety of Psilocybin, Ketamine, LSD, MDMA, and DMT for treating a variety of mental health conditions. While they remain highly regulated under the Controlled Substance Act, many state and local governments are progressively legalizing these psychedelics and other emerging therapies. This shift opens the door for entrepreneurs, investors, and others who want to explore the potential for implementing these substances in commercial ventures.
Leveraging our expertise in heavily regulated industries, we offer distinctive support to clients as they navigate the intricate web of federal, state, and local regulations in this dynamic and promising field.
Our Industries include:
Insights
Arizona’s Leap Forward in Psychedelic Research
April 7, 2025
A setback for psilocybin access? Ninth Circuit opposed DEA’s Rejection of exemption request.
February 26, 2025
As the NLRB pendulum swings: what employers need to know post-election
November 18, 2024